17 November 2026
by Joanne S. Eglovitch

FDA to refer to AI as ‘super intelligence’ going forward

FDA_Sign_260416_ALF.png
FDA headquarters in Silver Spring, Md. (credit: Ferdous Al-Faruque)

The US Food and Drug Administration (FDA) announced that, as of Monday, it will use the term “super intelligence” instead of “artificial intelligence” in all official correspondence, public communications, websites, reports, and policy documents.

The shift was prompted by an executive order (EO) signed by President Donald Trump in September that directs all executive departments and federal agencies to make this change.

The EO only applies only to executive branch agencies and does not affect private industry, Sydney White, an attorney with Wiley Rein LLP, told Focus. This means that pharmaceutical and medical device manufacturers will not need to make the terminology change. However, White noted that “private-sector organizations could be affected if any of the EO's directives are enacted into law.”

Christina Silcox, the research director for digital health at the Duke-Margolis Institute for Health Policy, told Focus that “I would consider this more of a semantic change than a meaningful change because neither artificial intelligence nor super intelligence have particularly strong definitions. In both cases, the terms are incredibly broad, and the technical definitions don’t necessarily match up well with common usage, which frequently leads to confusion.”

Silcox expressed concern that using the term “super intelligence” to describe all clinical and clinical-adjacent AI-enabled tasks might lead to an “over-reliance on the results by clinicians and patients.” She emphasized that health systems with effective governance should ensure that users understand what each specific AI tool does, when it should be used, and how to interpret and act on the results.

FDA said the term change will not affect existing guidance documents, regulations, Federal Register notices, and other previously issued FDA documents. The agency said that “where a statute or regulation uses ‘artificial intelligence’ or ‘AI’, FDA will continue to quote and cite those terms as written.” FDA also said it will make conforming edits to its public-facing documents “as part of each document’s next substantive revision and updating web content on its regular maintenance cycle.”

According to the EO, the term “AI” is considered outdated. “The terminology used by the Federal Government should reflect the transformative capabilities of these technologies and the limitless opportunities they create for the American people. Accordingly, the term “Super Intelligence” more appropriately captures the promise, potential, and rapidly advancing capabilities of these technologies.”

The EO directs the Assistant to the President for Science and Technology (APST), to provide the President with proposed legislative language that defines “Super Intelligence” within 60 days of the order.

FDA announcement, Executive order